Point72 Asia Singapore Pte. Ltd. Purchases 1,033 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Point72 Asia Singapore Pte. Ltd. raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 36.7% in the third quarter, HoldingsChannel reports. The firm owned 3,844 shares of the company’s stock after buying an additional 1,033 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Keros Therapeutics were worth $223,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KROS. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Arizona State Retirement System grew its position in shares of Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after acquiring an additional 1,130 shares during the period. Algert Global LLC increased its stake in shares of Keros Therapeutics by 10.6% in the 2nd quarter. Algert Global LLC now owns 15,700 shares of the company’s stock worth $717,000 after purchasing an additional 1,505 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in Keros Therapeutics in the 3rd quarter worth $89,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KROS shares. Bank of America cut their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Scotiabank assumed coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective for the company. Finally, Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Up 9.8 %

KROS stock opened at $62.28 on Wednesday. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -11.95 and a beta of 1.20. Keros Therapeutics, Inc. has a twelve month low of $27.31 and a twelve month high of $73.00. The business’s fifty day simple moving average is $59.67 and its two-hundred day simple moving average is $52.37.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period last year, the company earned ($1.33) EPS. Research analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.